A Phase 3 interventional study of Masupirdine 50 mg and Masupirdine 100 mg in Agitation and Alzheimer's Type Dementia, sponsored by Suven Life Sciences Limited. Active, not recruiting at 44 sites in 4 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Suven Life Sciences Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
This is a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment.
Approximately 375 participants will be enrolled at approximately 50 centers worldwide.
Study medication will be administered orally once-daily from Day 1 through Day 85. Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
This study's planned enrollment of 375 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Browse Psychomotor Agitation studies →Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet
Drug: Masupirdine 50 mg
Tablet
Drug: Masupirdine 100 mg
Tablet
Drug: Placebo
Tablet, Once Daily
Also known as: SUVN-502
Tablet, Once Daily
Also known as: SUVN-502
Matching Placebo Tablet, Once Daily
Cohen-Mansfield Agitation Inventory (CMAI)
Change in CMAI items score aligning to the International Psychogeriatric Association (IPA) agitation criteria domains (physical aggression, excessive motor activity, and verbal aggression). CMAI is a validated 29-item questionnaire to assess agitation. Each item is rated on a 7-point scale ranging from 1 "Never" to 7 "Several times per hour". Higher scores indicate worsening agitation.
Time frame: From Baseline to Week 12 visit
Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGI-C)
Change in mADCS-CGI-C. The mADCS-CGI-C is a modification of the ADCS-CGI-C instrument that focuses specifically on agitation. It is a 7-point Likert scale that ranges from marked improvement scored as 1 to marked worsening scored as 7. The range is from 1 to 7. Higher scores indicate worsening agitation.
Time frame: From Baseline to Week 12 visit
Plan to share: No
Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.
Of 23 phase 3 interventional studies under Psychomotor Agitation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 47. This study's planned 49 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suven Life Sciences Limited